NEW YORK (GenomeWeb News) – Accelerate Diagnostics today said that revenues for its first quarter rose 70 percent year over year.

The Tucson, Ariz.-based firm company, formerly called Accelr8 Technology, recorded $15,678 in revenues, compared to $9,197 a year ago. All revenues for the current and year-ago quarter came from its OptiChem business, the company said in its Form 10-Q filed with the US Securities and Exchange Commission, and the increase resulted from "fluctuations in partner sales volumes on which royalties were due the company."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.